Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective

•SGLT2 inhibitor are associated with significant cardiovascular and renoprotective benefits in HFrEF, CKD, T2DM. .•There is a spectrum of unfamiliar adverse effects including mycotic genital infections, diabetic ketoacidosis, and fractures.•A misunderstanding of the benefits and risks may lead to supotimal prescribing of SGLT2 inhibitors.•Benefits of SGLT2 inhibitors in HFrEF, CKD and T2DM populations far outweigh perceived risks.